A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
出版年份 2014 全文链接
标题
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
作者
关键词
-
出版物
NATURE MEDICINE
Volume 21, Issue 1, Pages 27-36
出版商
Springer Nature
发表日期
2014-12-09
DOI
10.1038/nm.3761
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties
- (2013) Vikas K. Bhat et al. BIOCHEMICAL PHARMACOLOGY
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- GLP-1/Glucagon Coagonism Restores Leptin Responsiveness in Obese Mice Chronically Maintained on an Obesogenic Diet
- (2013) C. Clemmensen et al. DIABETES
- Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
- (2013) K. M. Habegger et al. DIABETES
- A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice
- (2013) V. K. Bhat et al. DIABETOLOGIA
- A Novel Glucagon-like Peptide-1 (GLP-1)/Glucagon Hybrid Peptide with Triple-acting Agonist Activity at Glucose-dependent Insulinotropic Polypeptide, GLP-1, and Glucagon Receptors and Therapeutic Potential in High Fat-fed Mice
- (2013) Victor A. Gault et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure
- (2013) Minsuk Kim et al. NATURE MEDICINE
- Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
- (2013) Sharon A. Sadry et al. Nature Reviews Endocrinology
- Gastrointestinal hormones and bariatric surgery-induced weight loss
- (2013) Viorica Ionut et al. Obesity
- Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
- (2013) B. Finan et al. Science Translational Medicine
- Peptide lipidation stabilizes structure to enhance biological function
- (2013) Brian P. Ward et al. Molecular Metabolism
- Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents
- (2012) Jonathan W. Day et al. BIOPOLYMERS
- The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice
- (2012) K. Fosgerau et al. DIABETES OBESITY & METABOLISM
- Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat
- (2012) A. Bénardeau et al. DIABETES OBESITY & METABOLISM
- Fat: an evolving issue
- (2012) J. R. Speakman et al. Disease Models & Mechanisms
- Anti-obesity drugs: past, present and future
- (2012) R. J. Rodgers et al. Disease Models & Mechanisms
- GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic MaleApoE−/−Mice
- (2012) Naim Panjwani et al. ENDOCRINOLOGY
- Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21
- (2012) Timo D. Müller et al. JOURNAL OF PEPTIDE SCIENCE
- Targeted estrogen delivery reverses the metabolic syndrome
- (2012) Brian Finan et al. NATURE MEDICINE
- Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
- (2011) W Timothy Garvey et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
- (2011) Kishore M Gadde et al. LANCET
- GLP-1 and energy balance: an integrated model of short-term and long-term control
- (2011) Jason G. Barrera et al. Nature Reviews Endocrinology
- Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
- (2011) David B. Allison et al. Obesity
- A Novel Human-Based Receptor Antagonist of Sustained Action Reveals Body Weight Control by Endogenous GLP-1
- (2010) James T. Patterson et al. ACS Chemical Biology
- Taspoglutide, a novel human once-weekly GLP-1 analogue, protects pancreatic β-cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivo
- (2010) S. Uhles et al. DIABETES OBESITY & METABOLISM
- The metabolic actions of glucagon revisited
- (2010) Kirk M. Habegger et al. Nature Reviews Endocrinology
- Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
- (2009) A. Pocai et al. DIABETES
- A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
- (2009) Jonathan W Day et al. Nature Chemical Biology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now